China Health Group Limited Provides Major Update on Auditor’s Disclaimer and Financial Measures
Key Points for Investors
- Ongoing Efforts to Resolve Auditor’s Disclaimer of Opinion: The company is addressing the auditor’s disclaimer of opinion on its ability to continue as a going concern for the financial year ended 31 March 2025. This disclaimer is a significant concern for shareholders as it can impact investor confidence and share value.
-
Successful Fundraising Initiatives:
- Subscription Agreements: The company entered into subscription agreements, raising an estimated gross proceeds of approximately HK\$70 million.
- Rights Issue: A rights issue was successfully proposed and completed, raising a further estimated gross proceeds of HK\$15 million.
- Aggregate Net Proceeds: Both the subscriptions and rights issue were completed on 6 October 2025, raising total net proceeds of around HK\$80.9 million.
-
Debt Repayment and Renewal of Banking Facilities:
- The group fully repaid a bank borrowing of approximately HK\$5.4 million in February 2026.
- Secured a new banking facility with a credit limit of about HK\$4.6 million for two years, improving the company’s liquidity profile.
- Additional Share Subscription: On 26 February 2026, the company completed a new share subscription, raising further net proceeds of about HK\$25.27 million.
- Ongoing Assessment of Funding Needs: The Board is actively monitoring operational and funding requirements and is open to seeking additional financing as needed.
- Future Updates: The company has promised to provide further progress updates by 23 July 2026 until the auditor’s disclaimer of opinion is resolved.
Important Information for Shareholders
- Price Sensitive Developments: The resolution of the auditor’s disclaimer of opinion is critical and could significantly impact market perception and the share price. Investors should closely monitor further announcements.
- Stronger Financial Position: The successful capital raising activities and debt repayment have improved the group’s financial standing, potentially reducing risk and enhancing shareholder value.
- Liquidity and Funding Outlook: Access to new banking facilities and ongoing fundraising efforts offer improved confidence in the company’s ability to fund operations and strategic initiatives.
- Ongoing Uncertainty: Until the disclaimer of opinion is lifted, there remains some uncertainty and risk regarding the company’s ongoing financial health.
- Investor Caution: The Board expressly advises shareholders and investors to exercise caution when dealing in the company’s securities.
Board Composition
The Board currently consists of three executive directors (Cao Xu, Chung Ho, Ying Rensi), two non-executive directors (Ying Wei, Huang Lianhai), and three independent non-executive directors (Li Hongyi, Wu Hui, Yang Huimin).
Conclusion
China Health Group Limited has taken substantial actions to improve its financial footing and address the auditor’s disclaimer of opinion. These measures, including significant capital raising, debt repayment, and new banking facilities, represent important steps toward resolving critical uncertainties. Shareholders should remain vigilant and await further updates, especially as these developments have the potential to move the company’s share price significantly.
Disclaimer: This article is for informational purposes only. It does not constitute investment advice. Investors should exercise caution and consult with their financial advisors before making any investment decisions based on the information provided. The company has advised that shareholders and investors exercise caution when dealing in the company’s securities.
中國醫療集團有限公司——審計意見更新及財務措施重大公告
投資者重點信息
- 積極解決審計師保留意見： 公司正積極解決截至2025年3月31日止年度審計師對持續經營能力的保留意見。這對股東而言極為重要，或會影響投資者信心及股價表現。
-
成功資金募集：
- 認購協議： 公司已簽訂認購協議，預計集資約7,000萬港元。
- 供股： 成功提出供股方案，預計集資約1,500萬港元。
- 總淨集資額： 認購及供股於2025年10月6日完成，合共集資淨額約8,090萬港元。
-
債務償還及銀行新貸款：
- 集團於2026年2月全數償還銀行借款約540萬港元。
- 獲批新銀行信貸額度約460萬港元，為期兩年，有助改善集團流動資金狀況。
- 額外新股認購： 2026年2月26日完成新股認購，進一步集資淨額約2,527萬港元。
- 持續評估資金需求： 董事會會根據經營及資金需要，考慮進一步融資。
- 未來公告： 公司將於2026年7月23日前發佈進一步進展，直至保留意見問題獲得解決。
股東需知及可能影響股價之重點
- 敏感及影響股價事項： 保留意見的解決與否極為重要，可能會對市場及股價造成顯著影響，投資者應密切留意公司進一步公告。
- 財務狀況改善： 資金募集及償還債務，有助降低風險，提升股東價值。
- 流動資金及融資能力： 新銀行信貸及持續集資有助經營及發展需要，提升市場信心。
- 不確定因素仍存： 在保留意見未解除前，公司財務健康仍存在一定風險及不確定性。
- 股東及投資者應保持謹慎： 董事會明確建議股東及投資者於買賣公司證券時保持謹慎。
董事會組成
現時董事會包括三位執行董事（曹旭、鍾浩、應仁思）、兩位非執行董事（應偉、黃連海）及三位獨立非執行董事（李紅義、吳輝、楊惠敏）。
總結
中國醫療集團已採取多項措施提升財務狀況及解決審計保留意見，當中包括重大資金募集、清還借款及新銀行信貸。這些動作有望消除重大不確定性，對公司股價有潛在推動作用。投資者應保持關注，留意後續公告。
免責聲明： 本文僅供參考，並不構成投資建議。投資者應謹慎行事，並諮詢專業意見。公司亦建議股東及投資者於買賣公司證券時保持謹慎。
